Tóm tắt
Background: Heart failure is the consequence of many diseases that cause structural and/or functional disorders of the heart. Having a heart failure management program is essential to ensure patients receive optimal care and can improve clinical prognosis.
Objectives: 1. Describing realworld results of the Heart Failure Management Program at Hue Central Hospital; 2. Surveying the current status of prescribing drugs according to guidelines to treat heart failure in the program.
Studying methods: Implementation time is from July 2022 to September 2023 at Hue Central Hospital. The study design is a cross-sectional descriptive study with short-term longitudinal follow-up for at least 6 months.
Results: There were 734 patients including 445 men (60.6%) and 289 women (39.4%) with a mean age of 65.6 ± 15.4 years. The average follow-up time was 5.16 ± 3.53 months (the longest was 14 months). The prescription rates of ARNi, BB, MRA, SGLT2i were 55.9%, 77.9%, 78.7% và 76.5% respectively. After 6 months of management, these rates are 58.8%, 86.8%, 83.8%, 83.1% respectively. The average initial ejection fraction of the group of patients followed over 6 months was 34.5 ± 6.9%, after 6 months of management this rate increased to 39.9 ± 11.9%. The rate of rehospitalization due to heart failure decreased by 27.2% in the group of patients followed for more than 6 months. The mortality rate gradually decreased over time, from 4.4% to 1.7% after 6 months of follow-up.
Conclusion: The rate of optimal drug use in heart failure treatment improves over time, the death rate gradually decreases with each stage, but a lot of management measures need to be strengthened to avoid losing track of patients.